Table 5.

Clinical outcomes of patients infected with resistance to both BDQ and LZD

Patient ID	Patient category	Drug susceptibility	Mutation conferring BDQ resistance	Mutation conferring LZD resistance	Treatment regimen	Sputum culture conversion	Clinical outcome
040,012	Previously treated	MDR	WT	Cys154Arg (rplC)	Bdq/Lzd/Mfx/Cs/Am/Pto	8 weeks	Cured
010,121	Previously treated	XDR	Ile108Thr (Rv0678)	WT	Bdq/Lzd/Mfx/Cs/Cfz/Am	NA	Treatment failure

MDR, multidrug-resistance; XDR, extensive drug-resistance; BDQ, bedaquiline; LZD, linezolid; Mfx, moxifloxacin; Cs, cycloserine; Am, amikacin; Pto, protionamide; Cfz, clofazimine; NA, not available; WT, wild-type